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EDITORIAL
The role of pre-migration medical screening in high TB burden
countries
IN THE FOURTH ARTICLE of the IJTLD State of
the Art series on TB and migration in this issue of the
Journal, Paul Douglas and colleagues introduce an
interesting discussion around pre-migration medical
screening programmes for migrants, and their poten-
tial role in capacity building and disease prevention in
migrant-generating countries with a high prevalence
of tuberculosis (TB).1 Collectively, over 2 million
immigrants who are seeking visas for permanent
entry to five low-incidence TB countries—Australia,
Canada, New Zealand, the United Kingdom and the
United States—pass through these pre-migration
screening programmes every year, predominantly at
sites in India, China, the Philippines and Viet Nam.
The aim of these pre-migration screening pro-
grammes is to detect and treat active cases of TB (as
well as detecting multi- and extensively drug-resistant
TB), and thus support initiatives to reduce the burden
of TB in migrant-receiving low-incidence TB coun-
tries, where in many settings TB rates remain high
particularly in foreign-born nationals.2 Previously
published data suggest pre-migration screening pro-
grammes are effective as a broad package of measures
to ensure early diagnosis and treatment of migrants
with TB.3 However, Douglas et al. conclude that pre-
migration screening programmes may have addition-
al positive impacts that stem from the collaborative
efforts in high-burden TB countries, which include
resourcing and increasing laboratory capacity (in-
cluding drug susceptibility testing capacity) and drug
availability, improving the infrastructure for direct
observation of treatment, as well as building partner-
ships in high-burden countries to strengthen national
TB programmes overall. The authors highlight that
current pre-migration screening programmes poten-
tially have additional benefits in terms of provision of
health care worker training and tools for patient
education, and that without these programmes many
of these initiatives may not otherwise have been
possible.
These programmes undoubtedly offer one more
weapon in the armoury against the global threat of
TB—the cornerstone of which is to seek out and treat
active cases, which predominantly occur in low- and
middle-income countries. However, as such pre-
departure programmes gain momentum and are
expanded and resourced, robust research will be
required to assess the true benefit of these initiatives
among the wider population in high-burden, migrant-
sending countries, and to better understand the
potential role of these programmes in influencing
TB epidemiology in these contexts. As yet it is unclear
to what extent these programmes are cost-effective
and offer added value beyond merely resourcing the
countries through their national TB control pro-
grammes which can be targeted to the specific in-
country population requirements. Furthermore, ques-
tions remain around the long-term sustainability of
pre-departure screening programmes.
Care, too, is needed to better understand whether
pre-departure screening programmes are indeed
migrant-friendly, and the extent to which they
represent a barrier to individuals seeking to migrate.
The practice of excluding migrants at borders based
on health criteria is ominous: in Australia, a key
reason for why visas have been refused in the past has
been because migrants do not meet certain health
criteria when they are screened pre-arrival. And it is
only as recently as 2010 that the US government
changed a policy spanning two decades that refused
applications for short-term visas or lawful permanent
residence to foreign-born nationals based on a
positive diagnosis for the human immunodeficiency
virus. Only time will tell which direction the new US
administration will ultimately take on immigrant
health screening.
The reality is that by far the majority of migrants
from high-burden TB countries will bypass any kind
of pre-departure screening programme altogether,
and avoid or fail to be included in statutory
immigrant screening programmes post-arrival. This
will undoubtedly include undocumented migrants,
some of whom will be at high risk for TB but who are
afraid of approaching health services because of
perceived or real links to immigration law enforce-
ment. It is well understood, therefore, that multiple
approaches to immigrant screening are needed in
low-incidence settings, given that TB incidence rates
remain high in migrants several years after reloca-
tion.4,5 Key to tackling TB in migrant-receiving, low-
incidence TB countries is to ensure that migrants can
access timely screening and health care should
symptoms develop post-arrival. Going forward, this
will involve tackling the considerable disparities in
health care access faced by many migrants, including
screening for TB and other infections,6,7 and the
development of innovative strategies that take into
account the unique social and cultural barriers faced
by migrants to ensure uptake of screening and
treatment completion for both latent and active TB.
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A more equitable approach to eliminating TB in
countries such as the United States, Canada, Austra-
lia, New Zealand and the United Kingdom, therefore,
will be to better resource and promote timely access
to primary health care and screening for all at-risk
migrant groups living there.
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